Related Experiment Video
Updated: Jan 17, 2026
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a
Jing Tong Tan1, Xianhua Mao1, David Tak-Wai Lui1
1Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Background:
Effect of glycaemic control on pancreatic cancer (PC) development in patients with long-standing type 2 diabetes (T2D) remains unclear.
Objective:
To investigate effects of glycaemic control on PC development in patients with T2D.
Design:
Retrospective cohort study.
Methods:
Adults from a territory-wide healthcare registry were followed from T2D diagnosis until PC, death, pancreatectomy or end of study (December 2020). Exclusions were PC within 3 years after T2D diagnosis (addressing reverse causality), prior PC, immunoglobulin G4 disease and pancreatectomy. The primary outcome was PC and secondary outcomes included PC-related and all-cause mortality. Optimal glycaemic control throughout follow-up was defined as time-weighted mean haemoglobin A1c (A1c)<7%; with time-weighted mean fasting glucose (FG)≤7 mmol/L as secondary analysis. Adjusted HR (aHR) was estimated using Cox models with propensity score adjustment for covariates including demographics, diabetes complications, comorbidities and medications.
Results:
Among 458 331 patients (median age: 59.8 (P25-P75: 51.8-68.5) years; 51.2% male), there were 1382 (0.3%; 2.8 per 10 000 person-years) PC, 922 (0.2%; 1.9 per 10 000 person-years) PC-related deaths, and 70 936 (15.5%; 142.9 per 10 000 person-years) deaths over a median follow-up of 9.9 (P25-P75: 7.4-14.1) years. Optimal glycaemic control was associated with lower PC risk-A1c<7%(aHR: 0.43; 95% CI: 0.37 to 0.48) and FG≤7 mmol/L (aHR: 0.71; 95% CI: 0.63 to 0.80). Optimal control of both A1c and FG conferred lowest PC risk (aHR: 0.39; 95% CI: 0.33 to 0.46). PC risk increased stepwise with A1c (Ptrend<0.001), with aHRs from 1.85 (A1c 7.0-7.5%) to 4.61 (A1c≥9.0%). Every 1% rise in A1c and 1 mmol/L rise in FG increased PC risk by 46% and 14%, respectively. Optimal control is also associated with lower PC-related mortality (aHR: 0.35; 95% CI: 0.30 to 0.41) and all-cause mortality (aHR: 0.83; 95% CI: 0.82 to 0.85).
Conclusion:
Optimal glycaemic control was associated with lower PC risk in T2D. Further multicentre cohort studies are warranted to confirm its oncopreventive strategy.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...